Long KMPH below $10
FDA approval with potential short squeeze. Without these catalyst the market cap still suggests that it is undervalued with the new addressable market of KP415/AZSTARYS
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.